Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
about
Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral painNon-systemic drugs: a critical reviewAdvances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotideLinaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adultsResponders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-CEmerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.Sildenafil normalizes bowel transit in preclinical models of constipationTenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipationLoss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrierLuminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Linaclotide - a secretagogue and antihyperalgesic agent - what next?Review article: Linaclotide for the management of irritable bowel syndrome with constipationTreatment of irritable bowel syndrome: beyond fiber and antispasmodic agents.Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C.Colitis decreases mechanosensitive K2P channel expression and function in mouse colon sensory neuronsBacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study.Optimal management of constipation associated with irritable bowel syndromeLinaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialAdvancing treatment options for chronic idiopathic constipation.Chronic constipation: new diagnostic and treatment approachesA 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationAnti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models.Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic ConstipationRegulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.Management Strategies for Abdominal Bloating and Distension.Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome.Linaclotide.Novel pharmacological therapies for management of chronic constipation.Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.Investigational agents for the irritable bowel syndrome.The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
P2860
Q26863234-7FEA02A7-E1DC-449A-BEFC-E419CA7868D9Q26863371-25B3358F-C70F-4D02-A2F3-EF54ED316D03Q26865304-ECFA0268-898C-4184-8E6C-A9F81AA0333CQ27010449-DE71152C-A6A1-403E-97E0-8948B6CBE642Q30724990-BEA32085-6449-4FAE-BCAD-123A4D1395F0Q33586854-0C18963B-7BF9-4467-BC52-D384119B29ECQ33610799-C8DA5D74-0642-4F7C-8FD5-C864F1AF95E8Q33639963-3777A749-9AC8-4E3E-BF56-DA7D8A355B46Q33695487-D107D4EF-8AFB-4E08-AC7A-10EA0FFFFF2FQ33816018-AB1D0567-A265-4A2A-9019-F847E724444BQ33854983-D80998EB-D973-4B12-B21D-6CE4351BCF47Q33958710-3B87B861-E4D0-4259-93AE-AECB5A9B766AQ34254749-3B79C9F3-2D30-4FFB-A899-AAAA134FA311Q34309302-C4F8E34A-7B38-4545-BFCA-CA437A5DF77DQ34323319-12371104-967F-4F66-9453-E338CBE754F1Q34478089-E63715EA-2523-41DC-8C69-465A730BDB6AQ34686723-018F8618-9A60-44A4-8658-2FFE3E3DBDBAQ35008626-31686163-8465-41AE-BEBE-192351449A8DQ35018460-911DCF93-9AF2-4D60-A3A6-C1F225CD9FC0Q35044200-07935D8B-EFEF-4C86-A56D-2C3862C1231FQ35087098-C34B7F8B-E1F0-41AD-BC24-04E7C08F612BQ35155933-AFC69BE1-0E7A-4F26-993C-0FF15A1B7873Q35161361-6E805192-09DF-4125-B428-E90D5D33F8CEQ35586543-E079FB29-7C8C-4D01-98BD-5B8BD15D7321Q35723125-512286E1-BC68-4846-BB7D-FF6730E4585EQ35858864-0255253E-91CA-4342-8E81-1FE2E8FFE919Q36072686-E70D9710-A8D0-4303-A817-CECAE243B394Q36417684-05AA69BD-71FE-4676-91EF-8690EE967C84Q36500198-099FEDFB-BC11-4A72-96EF-E0731A60FE04Q36801233-B82A9925-1A14-4EEC-8A30-B89CD553AADAQ36867743-CE971DE0-D928-4C6B-A84A-A5BDFE75814CQ37190545-2ED7D73B-7AE8-43A9-BD83-5876B153A0E0Q37253910-2D8CD880-F3E5-46ED-94E4-0638ADE38BD8Q37340041-89F64C0E-CAEE-4639-8306-7C5227360B0FQ37394824-1281CD6F-1D3D-4CF2-8BCB-D6D00FCC9EA1Q37671189-96C29E3C-00BE-4822-910C-45AD84280895Q37699695-49D391BB-2B73-4E6A-A802-51FCD743FD1CQ37788218-1F5343EA-30C7-4EB7-B683-B0A554C5558AQ37859025-6BE0AB6B-74F0-4B43-BC5C-1400D3629D32Q37886156-752D1833-66F9-4F8B-AA1D-12995EDD2AAA
P2860
Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@ast
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@en
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@nl
type
label
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@ast
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@en
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@nl
prefLabel
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@ast
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@en
Guanylate cyclase C-mediated a ...... odent models of visceral pain.
@nl
P2093
P1476
Guanylate cyclase C-mediated a ...... rodent models of visceral pain
@en
P2093
A P Bryant
C Beaufrand
H Eutamene
J Fioramonti
M G Currie
P304
P356
10.1111/J.1365-2982.2009.01385.X
P577
2009-08-25T00:00:00Z